Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Encorafenib Plus Binimetinib in Patients With Locally Advanced, Unresectable or Metastatic BRAFV600-mutated Melanoma: a Multi-centric, Multinational, Prospective, Longitudinal, Non-interventional Study in Germany, Austria and Switzerland - BERING MELANOMA

Next Previous
Trial Profile

Encorafenib Plus Binimetinib in Patients With Locally Advanced, Unresectable or Metastatic BRAFV600-mutated Melanoma: a Multi-centric, Multinational, Prospective, Longitudinal, Non-interventional Study in Germany, Austria and Switzerland - BERING MELANOMA

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Binimetinib (Primary) ; Encorafenib (Primary)
  • Indications Brain metastases; Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms BERING; BERING MELANOMA
  • Sponsors Pierre Fabre

Most Recent Events

  • 07 Jun 2022 Second Interim results (n=200) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 08 Jun 2021 According to Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology, the second interim analysis will be performed after enrollment of 200 patients and will include an initial analysis of effectiveness data.
  • 08 Jun 2021 First Interim results (n=100; till date) presented at the 57th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top